ClinicalTrials.gov
public full text
Public Domain
Oral CBP-0276 or Placebo in Adults With Active Psoriatic Arthritis (PsA)
Randomized trial aimed to assess in adults with PsA the effect of oral CBP-0276 administrated at a dose of 200mg QD, or 800mg QD vs. Placebo for CBP-0276 for 24 weeks. Primary outcome is the change at least 20% on severity of symptoms eat week 24, using the American College Rheumatologic Score (ACR) and key secondary outcomes are the change on ACR20% at week 16 and ACR50/70% at week 24. Eligible patients will be randomly assigned (1:1:1) to receive oral CBP-0276 200mg QD, 800mg QD or placebo for CBP-0276 for 24 weeks
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- CBD Treatment in Hand Osteoarthritis and Psoriatic Arthritis.#826645
- QA102 Phase 1 Study in Healthy Young and Older Adult Subjects#1112547
- A Study With GLPG1972 in Osteoarthritis Subjects#905763
- Cannabidiol Treatment in Patients With Early Psychosis#907182
- MIVetsCan: Cannabidiol (CBD)-Care Trial#1031331
Record · ID 896240
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive